# PREventing Second Cancers With DOSTARlimab

> **NCT05855811** · PHASE2 · RECRUITING · sponsor: **Centre Leon Berard** · enrollment: 400 (estimated)

## Conditions studied

- Recurrent Cancer
- Primary Cancer
- Second Cancer

## Interventions

- **DRUG:** Dostarlimab

## Key facts

- **NCT ID:** NCT05855811
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-26
- **Primary completion:** 2028-07-26
- **Final completion:** 2029-03-26
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2024-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05855811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05855811, "PREventing Second Cancers With DOSTARlimab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05855811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*